Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency

References

• Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor WI deficiency. Semin Thromb Hemost 2000;26:401–405.
   PubMed Web of Science ®Google Scholar
• Hoffinan M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb Haemost 2001;85: 958–965.
   PubMed Web of Science ®Google Scholar
• Cooper DN, Millar DS, Wacey A, Banner DW, Tuddenham EG. Inherited factor VII deficiency: Molecular genetics and pathophysiology. Thromb Haemost 1997;78:151–160.
   Web of Science ®Google Scholar
• Herrmann FH, Wulff K, Auberger K, Aumann V, Bergmann F, Bergmann K, Bratanoff E, Franke D, Grundeis M, Kreuz W, Lenk H, Losonczy H, Maak B, Marx G, Mauz-Korholz C, Pollmann H, Serban M, Sutor A, Syrbe G, Vogel G, Weinstock N, Wenzel E, Wolf K. Molecular biology and clinical manifestation of hereditary factor WI deficiency. Semin Thromb Hemost 2000;26:393–400.
   PubMedGoogle Scholar
• Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, Wulff K, Schved JF, Auerswald G, Ingerslev J, Bernardi F. International factor VII deficiency study group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005;93: 481–487.
   Google Scholar
• Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004;10:593–628.
   Google Scholar
• Peyvandi F, Mannucci PM, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia 1997;3:242–246.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999;82:1207–1214.
   PubMed Web of Science ®Google Scholar
• Roberts HR, Lefkowitz JB. Inherited disorders of prothrombin conversion. 3rd ed. Philadelphia, USA: Lippincott JB; 1994. p 206–208.
   Google Scholar
• Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor WI in the treatment of congenital factor WI deficiencies. Vox Sanguinis 1999;77:131–136.
   Google Scholar
• Ragni MV, Lewis JH, Spero JA, Hasiba U. Factor WI deficiency. Am J Hematol 1981;10:79–88.
   PubMed Web of Science ®Google Scholar
• Acharya SS, Coughlin A, Dimichele DM. Rare bleeding disorder registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248–256.
   Google Scholar
• Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-WI-deficient patients. Haemophilia 1997;3:215–218.
   PubMed Web of Science ®Google Scholar
• Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001;7(Suppl 1):16–22.
   Google Scholar
• Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–1252.
   Google Scholar
• Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia 1998;4:689–696.
   PubMed Web of Science ®Google Scholar
• Kohler M, Hellstern P, Pindur G, Wenzel E, von Blohn G. Factor VII half-life after transfusion of a steam-treated prothrombin complex concentrate in a patient with homo-zygous factor WI deficiency. Vox Sanguinis 1989;56:200–201.
   Google Scholar
• White GC, Lundblad RL, Kingdon HS. Prothrombin complex concentrates: Preparation, properties, and clinical uses. Curr Topics Hematol 1979;2:203–244.
   Google Scholar
• Ramanarayanan J, Krishnan G, Hernandez-Ilizaliturri MD. Factor WI. eMedicine, Available from: http://www.emedicine.com/med/topic3493.htm. Accessed 28/01/05.
   Google Scholar
• United Kingdom Haemophilia Centre Doctors’ Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9:1–23.
   Web of Science ®Google Scholar
• Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999;5:253–259.
   PubMed Web of Science ®Google Scholar
• Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003;121:477–481.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999;82:1778.
   Google Scholar
• Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94:3951–3953.
   PubMed Web of Science ®Google Scholar
• Poon MC, D’Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M. International data collection on recombinant factor WIa and congenital platelet disorders study group. Prophylactic and therapeutic recombinant factor Vila administration to patients with Glanzmann’s thrombasthenia: Results of an international survey. J Thromb Haemost 2004;2:1096–1103.
   Google Scholar
• Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recom-binant factor VIIa. Thromb Haemost 1996;75:981–982.
   PubMed Web of Science ®Google Scholar
• Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against von Willebrand factor. Haemostasis 1996;26 (Suppl 1):150–154.
   Google Scholar
• Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand’s disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000;83:633–634.
   PubMed Web of Science ®Google Scholar
• Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand’s disease, controlled with recombinant factor VIIa. Blood Coag Fibrinol 2001;12:211–213.
   Google Scholar
• Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005 July 26 Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
   PubMed Web of Science ®Google Scholar
• Poon MC, d’Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International registry on recombinant factor VIIa and congenital platelet disorders group. Blood Coag Fibrinol 2000;11 (Suppl 1):S55–S68.
   Google Scholar
• Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VIIa (NovoSeven) in a patient with factor XI deficiency and a circulating antic-oagulant. Blood Coag Fibrinol 2001;12:551–553.
   Google Scholar
• Lawler P, White B, Pye S, Hermans C, Riddell A, Costello C, Brown S, Lee CA. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002;8:145–148.
   PubMed Web of Science ®Google Scholar
• Billio A, Pescosta N, Rosanelli C, Amaddii G, Fontanellia F, Coser P. Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency. Blood Coag Fibrinol 1997;8:249–250.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Visanuyothin N, Puapunwattana S, Chaivi-suth A, Rasmidat P, Charoenkwan P, Chiemchanya S. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thailand 2002;85(Suppl 4):S1059–S1064.
   Google Scholar
• Eskandari N, Feldman N, Greenspoon JS. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obst Gynecol 2002;99:935–937.
   Google Scholar
• Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion 2004;44:1562–1566.
   Google Scholar
• Maimon M, Bernstein T, Kenet G, Kapelushnik J. Recombi-nant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta. J Pediat Hematol/On-col 2003;25:591.
   PubMed Web of Science ®Google Scholar
• Mathijssen NC, Masereeuw R, Verbeek K, Lavergne JM, Costa JM, van Heerde WL, Novakova IR. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004;125:494–499.
   Google Scholar
• Niikura T, Nishikawa T, Saegusa Y, Fujishiro T, Yoshiya S, Kurosaka M. Total hip arthroplasty in severe congenital factor VII deficiency: Successful use of recombinant activated factor VII for hemostasis. J Arthroplast 2005;20:396–400.
   PubMed Web of Science ®Google Scholar
• Tcheng WY, Donkin J, Konzal S, Wong WY. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency. Haemophilia 2004;10:295–298.
   PubMed Web of Science ®Google Scholar
• White B, Martin M, Kelleher S, Browne P, McCann SR, Smith OP. Successful use of recombinant FVIIa (NovoSeven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency. Br J Haematol 1999;106:254–255.
   PubMed Web of Science ®Google Scholar
• White B, O’Connor H, Smith OP. Successful use of recombinant VIIa (NovoSeven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency. Blood Coag Fibrinol 2000;11:155–157.
   PubMed Web of Science ®Google Scholar
• Mariani G, Konlde BA, Ingerslev J. Congenital factor VII deficiency: Therapy with recombinant activated factor WI—a critical appraisal. Haemophilia 2006;12:19–27.
   Google Scholar
• Kessler C. Haemostasis.com: Clinical experiences in the investigational use of rFTIIa in the management of severe haemorrhage. Br J Haematol 2004;127:230.
   Web of Science ®Google Scholar
• Brummel Ziedins K, Rivard GE, Pouliot RL, Butanas S, Gissel M, Parhami-Seren B, Mann KG. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2:1735–1744.
   PubMedGoogle Scholar
• Mariani G, Mazzucconi MG. Factor WI congenital deficiency. Clinical picture and classification of the variants. Haemostasis 1983;13:169–177.
   Google Scholar
• Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004;2(6):899–909.
   PubMed Web of Science ®Google Scholar
• Roberts HR. Recombinant factor VIIa (NovoSeven°) and the safety of treatment. Semin Haematol 2001;38:48–50.
   PubMed Web of Science ®Google Scholar